You are here: Industry Insights > iPSC

News List

Evotec, Boehringer Ingelheim Partner to Tackle Ophthalmologic Disorders contractpharma
January 25, 2022
Aims to identify and validate promising targets and new approaches for therapeutic interventions.
Fujifilm Cellular Dynamics and PhenoVista Biosciences Enter Drug Discovery Partnership contractpharma
January 07, 2022
Enables access to services for phenotypic and high content screening imaging using iPSC-derived differentiated cells.
PBS Biotech secures $10 million to expand cell therapy manufacturing equipment portfolio cphi-online
August 19, 2021
The capital will be used to expand and industrialise the company's range of single-use bioreactor systems and contract process development services
Orizuru Therapeutics Launches Operations as Research and Development-driven Company for Products Including induced Pluripotent Stem Cell (iPSC) Regenerative Medicine prnasia
August 10, 2021
Orizuru Therapeutics Inc. announced the launch of its operations on June 1, 2021. OZTx is a research and development-driven company focusing on the development of iPSC―based regenerative medicine and the application of iPSC technology, and is based at ...
Catalent Completes RheinCell Therapeutics Acquisition contractpharma
August 05, 2021
Catalent has completed the acquisition of RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).
Catalent to Acquire RheinCell Therapeutics contractpharma
June 28, 2021
Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has reached an agreement to acquire RheinCell Therapeutics GmbH ...
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
June 23, 2021
Century Therapeutics (NASDAQ: IPSC) today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share
Kite and Shoreline Biosciences enter partnership to develop novel allogeneic cell therapies expresspharma
June 18, 2021
Kite, a Gilead Company and Shoreline Biosciences announced a strategic partnership to develop novel cell therapies across a variety of cancer targets.
Exacis Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors americanpharmaceuticalreview
April 01, 2021
Exacis Biotherapeutics announced several steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates.
Fujifilm and Sana Biotechnology Enter Cell Therapy Partnership contractpharma
March 18, 2021
Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, a company focused on creating and delivering engineered cells as medicines, have entered a license ...

Previous page 1 2 3 Next page